secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celcuity Inc. (CELC)
CIK:        0001603454
Form:       8-K
Filed at:   2026-10-02T12:05:13+00:00
Accession:  0001193125-26-411297
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Celcuity adds ex-Incyte/Celgene CFO David Gryska to board; cites first FDA approval of REVTORPYK
--------------------------------------------------------------------------------

- Board expanded from eight to nine members; David W. Gryska appointed effective October 1, 2026, serving through the 2027 Annual Meeting.
- Gryska was EVP and CFO of Incyte and SVP and CFO of Celgene, and earlier VP Finance/CFO at Scios and a partner at Ernst & Young.
- He joins the Audit and Compensation Committees and is deemed independent under Nasdaq listing standards and SEC rules.
- Pro-rated director pay: $70,000 annual cash retainer and $100,000 annual equity award; granted 893 RSUs vesting at the 2027 annual meeting or April 30, 2027.
- CEO Brian Sullivan links the hire to the company's transition to commercial stage after the first FDA approval for REVTORPYK in advanced breast cancer and gedatolisib development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1603454/000119312526411297/0001193125-26-411297-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1603454/000119312526411297/celc-20261001.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-411297

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer